Abstract
Prostacyclin (PGI2) inhibits platelet aggregation and vasoconstriction. PGI2 synthase (PGIS), a catalyst of PGI2 formation from prostaglandin H2, is widely distributed and predominantly found in vascular endothelial and smooth muscle cells. Vane et al. first discovered PGI2 in 1976, for which they received the Nobel Prize in medicine and physiology in 1982. However, the later discovery of nitric oxide (NO), which also resulted in a Nobel Prize for the scientists involved, led to less attention being focused on PGI2. The reason for this is somewhat perplexing and may have been due to the lack of information on how to correctly use PGI2. Current findings suggest that researchers concentrated too much effort on the therapeutic effects of PGI2, while largely ignoring the potential for preventative effects. In addition, PGI2 was shown to be effective against diseases in some studies but was without effect in others. The present paper contains a review of PGI2 and PGIS, in addition to an examination of the relationship between PGIS gene mutations and cardiovascular diseases. PGI2 analogues that can be used in the prevention of cardiovascular diseases are also discussed.
Keywords: Prostacyclin, association study, prevention, cardiovascular diseases, mutation, polymorphism
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title: Prostacyclin Analogues: Prevention of Cardiovascular Diseases
Volume: 4 Issue: 4
Author(s): Tomohiro Nakayama
Affiliation:
Keywords: Prostacyclin, association study, prevention, cardiovascular diseases, mutation, polymorphism
Abstract: Prostacyclin (PGI2) inhibits platelet aggregation and vasoconstriction. PGI2 synthase (PGIS), a catalyst of PGI2 formation from prostaglandin H2, is widely distributed and predominantly found in vascular endothelial and smooth muscle cells. Vane et al. first discovered PGI2 in 1976, for which they received the Nobel Prize in medicine and physiology in 1982. However, the later discovery of nitric oxide (NO), which also resulted in a Nobel Prize for the scientists involved, led to less attention being focused on PGI2. The reason for this is somewhat perplexing and may have been due to the lack of information on how to correctly use PGI2. Current findings suggest that researchers concentrated too much effort on the therapeutic effects of PGI2, while largely ignoring the potential for preventative effects. In addition, PGI2 was shown to be effective against diseases in some studies but was without effect in others. The present paper contains a review of PGI2 and PGIS, in addition to an examination of the relationship between PGIS gene mutations and cardiovascular diseases. PGI2 analogues that can be used in the prevention of cardiovascular diseases are also discussed.
Export Options
About this article
Cite this article as:
Nakayama Tomohiro, Prostacyclin Analogues: Prevention of Cardiovascular Diseases, Cardiovascular & Hematological Agents in Medicinal Chemistry 2006; 4 (4) . https://dx.doi.org/10.2174/187152506784111463
DOI https://dx.doi.org/10.2174/187152506784111463 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Aβ Monomers, Oligomers and Fibrils: Structural Features
Current Bioactive Compounds Study of Prolactin Permeation Through the Pericardium and Its Bioavailability
Protein & Peptide Letters The Therapeutic Potential of Stem Cells in Amyotrophic Lateral Sclerosis
Current Signal Transduction Therapy The Role of Heat Shock Protein (HSP) in Atherosclerosis: Pathophysiology and Clinical Opportunities
Current Medicinal Chemistry Phytosterols in Physiological Concentrations Target Multidrug Resistant Cancer Cells
Medicinal Chemistry Clinical Implications of CYP2D6 Genetic Polymorphism During Treatment with Antipsychotic Drugs
Current Drug Targets Interaction Between Platelets and Cytokines - A Possible Role in the Pathogenesis of Preeclampsia
Vascular Disease Prevention (Discontinued) MicroRNA in Aging: From Discovery to Biology
Current Genomics Fish Oil Fatty Acids as Cardiovascular Drugs
Current Vascular Pharmacology Synthesis and Anti-tubercular Activity of 6-(<i>4</i>-Chloro/Methyl-phenyl)-4- Arylidene-4,5-dihydropyridazin-3(2<i>H</i>)-one Derivatives Against Mycobacterium tuberculosis
Letters in Drug Design & Discovery Methodologic Issues in the Validation of Putative Biomarkers and Surrogate Endpoints in Treatment Evaluation for Systemic Lupus Erythematosus
Endocrine, Metabolic & Immune Disorders - Drug Targets Metabolic and Cardiovascular Ageing Indices in Relation to Glycated Haemoglobin in Healthy and Diabetic Subjects
Current Aging Science Cross-Talk Between Adipose Tissue Health, Myocardial Metabolism and Vascular Function: The Adipose-Myocardial and Adipose-Vascular Axes
Current Pharmaceutical Design Biodegradable Biomaterials
Recent Patents on Biomedical Engineering (Discontinued) Lipoprotein (a) Evolution: Possible Benefits and Harm. Genetic and Non-Genetic Factors Influencing its Plasma Levels
Current Medicinal Chemistry Omentin: Linking Metabolic Syndrome and Cardiovascular Disease
Current Vascular Pharmacology Bortezomib – First Therapeutic Proteasome Inhibitor for Cancer Therapy: A Review of Patent Literature
Recent Patents on Anti-Cancer Drug Discovery Imaging Subclinical Atherosclerosis: Where Do We Stand?
Current Cardiology Reviews Daclatasvir: The First of a New Class of Drugs Targeted Against Hepatitis C Virus NS5A
Current Medicinal Chemistry Biologic Therapy in Inflammatory and Immunomediated Arthritis: Safety Profile
Current Drug Safety